Archive for October 2014
How Alcon & Google Could Change The Contact Lens
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 013″] At the recent Ophthalmology Innovation Summit in Chicago, Google and Alcon executives shared the origins and potential outcomes of the partnership between the two companies. Initially, they hope to develop a contact lens capable of measuring the wearer’s glucose levels but future applications are even bolder.
Read MoreHow Alcon and Google Could Change The Contact Lens
Moderator: Gilbert H. Kliman, MD Dr. Gil Kliman leads the medical device investment team at InterWest Partners and invests in a broad array of healthcare opportunities, with a special interest in ophthalmology and digital health. View Full Profile Panelists: Brian P. Otis, PhD Dr. Brian Otis is the founder of Google [x]’s smart contact lens…
Read MoreNASA-Backed Entity Enlists Industry To Battle Eye Disorders Caused By Space Travel
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 012″] In this week’s podcast, Dorit B. Donoviel, PhD, Deputy Chief Scientist and Industry Forum Lead of the National Space Biomedical Research Institute, and Randy McDonald, Founder and President of the Magnum Group, expand on an announcement made at last week’s Ophthalmology Innovation Summit. A new joint effort between industry and…
Read MoreDirk Sauer Oversees Novartis’ Promising & Productive Ophthalmic Pipeline
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 011″] As Global Head of Development Franchise Ophthalmics at Novartis, Dirk Sauer has overseen the development of Novartis’ blockbuster Lucentis. Now, his focus is on the pharmaceutical giant’s pipeline of retina compounds, including many in the early stages. Hear how Sauer views innovation, both inside and outside of Novartis. Podcast Guest…
Read MoreHow Do You Talk to an Angel?
Ophthalmic Surgeon, Eric D. Kanter, MD, of Retina-Vitreous Consultants, balances his work at his busy New Jersey practice with his commitments as a principal member of Mid Atlantic Bio Angels. Members of MABA invest between $250,000 to $500,000 in life science start-ups of all types. Submissions for review have included ophthalmic drug, various types of…
Read MoreGobiquity Goes Big In Mobile Imaging Diagnostics
[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 010″] Gobiquity CEO Michael Brownell breaks down the mobile ophthalmology market from the viewpoint of a start-up that’s set to change how kids are diagnosed with amblyopia, the number one cause of vision loss in kids. Podcast Guest Michael Brownell Michael Brownell joined Gobiquity as CEO in 2012, with prior experience…
Read More